{"entity":{"id":"nct06084806","kind":"trial","name":"Test-retest Evaluation of [18F]F-AraG PET","aka":[],"tldr":"A phase 2 trial of [18F]F-ARAG PET in non-small-cell lung cancer, run by CellSight Technologies, Inc., now recruiting.","summary":"Test-retest Evaluation of [18F]F-AraG PET is a phase 2 interventional study registered as NCT06084806 by CellSight Technologies, Inc., with 10 participants planned, started 2023-10-31 and due to reach its primary completion in 2025-10-31. Interventions recorded: [18F]F-ARAG PET.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06084806","url":"https://clinicaltrials.gov/study/NCT06084806"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["nsclc"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06084806","phase":"2","setting":"Test-retest Evaluation of [18F]F-AraG PET in Non-small Cell Lung Cancer (NSCLC) Patients","sponsor":"CellSight Technologies, Inc.","enrolled":10,"outcomes":[]},"route":"/trials/nct06084806/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}]}}